Cipla will soon launch Synchrobreathe, an inhaler intended to aid in the management of obstructive airway disease.

Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”

Cipla made a presentation on Synchrobreathe at the South Africa Thoracic Society (SATS) conference in Cape Town (7-10 August 2015) where around 200 healthcare providers, pulmonologists, thoracic surgeons and other specialists present.

Read the full story at